XML 31 R20.htm IDEA: XBRL DOCUMENT v3.21.2
Note 12 - Segment Information
 6 Months Ended
Sep. 30, 2021
Notes to Financial Statements  
Segment Reporting Disclosure [Text Block]

Note 12. Segment Information

 

As of September 30, 2021, we had four reportable segments: Sterilization and Disinfection Control, Biopharmaceutical Development, Instruments, and Continuous Monitoring. 

 

  

Three Months Ended September 30,

  

Six Months Ended September 30,

 
  

2021

  

2020

  

2021

  

2020

 

Total revenues (a)

                

Sterilization and Disinfection Control

 $14,033  $11,552  $29,183  $24,619 

Biopharmaceutical Development

  10,555   9,131   19,432   15,080 

Instruments

  6,970   7,558   14,532   15,238 

Continuous Monitoring

  4,282   3,619   7,613   6,864 

Total revenues (a)

 $35,840  $31,860  $70,760  $61,801 
                 

Gross profit (loss)

                

Sterilization and Disinfection Control

 $10,486  $8,770  $21,914  $18,790 

Biopharmaceutical Development

  6,601   6,212   11,293   10,678 

Instruments

  4,112   4,852   8,772   9,541 

Continuous Monitoring

  2,016   1,368   3,468   2,552 

Reportable segment gross profit

  23,215   21,202   45,447   41,561 

Corporate and Other (b)

  (75)  83   (96)  64 

Gross profit

 $23,140  $21,285  $45,351  $41,625 

Reconciling Items:

                

Operating expenses

  18,939   16,815   38,027   33,585 

Operating income

  4,201   4,470   7,324   8,040 

Nonoperating (income) expense, net

  (342)  2,086   1,363   4,902 

Earnings before income taxes

 $4,543  $2,384  $5,961  $3,138 

 

 

(a)

Intersegment revenues are not significant and are eliminated to arrive at consolidated totals.

 

(b)

Non-reportable operating segments and unallocated corporate expenses are reported within Corporate and Other. 

 

The following table sets forth inventories by reportable segment. Our chief operating decision maker is not provided with any other segment asset information. 

 

  

September 30,

  

March 31,

 
  

2021

  

2021

 

Sterilization and Disinfection Control

 $2,187  $2,333 

Biopharmaceutical Development

  3,706   4,162 

Instruments

  4,566   3,253 

Continuous Monitoring

  1,658   1,430 

Total inventories

 $12,117  $11,178